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Rett syndrome (RTT) is a devastating neurodevelopmental disorder that has no cure.
Patients show regression of acquired skills, motor, and speech impairment, cardio-
respiratory distress, microcephaly, and stereotyped hand movements.The majority of RTT
patients display mutations in the gene that codes for the Methyl-CpG binding protein 2
(MeCP2), which is involved in the development of the central nervous system, especially
synaptic and circuit maturation.Thus, agents that promote brain development and synaptic
function are good candidates for ameliorating the symptoms of RTT. In particular, insulin-
like growth factor 1 (IGF1) and its active peptide (1–3) IGF1 cross the Blood Brain Barrier,
and therefore are ideal treatments for RTT Indeed, both (1–3) IGF1 and IGF1 treatment
significantly ameliorates RTT symptoms in a mouse model of the disease In a previous
study, we established that IGF1 is safe and well tolerated on Rett patients. In this open
label clinical case study, we assess the safety and tolerability of IGF1 administration in two
cycles of the treatment. Before and after each cycle, we monitored the clinical and blood
parameters, autonomic function, and social and cognitive abilities, and we found that IGF1
was well tolerated each time and did not induce any side effect, nor it interfered with the
other treatments that the patient was undergoing. We noticed a moderate improvement in
the cognitive, social, and autonomic abilities of the patient after each cycle but the benefits
were not retained between the two cycles, consistent with the pre-clinical observation
that treatments for RTT should be administered through life. We find that repeated IGF1
treatment is safe and well tolerated in Rett patients but observed effects are not retained
between cycles.These results have applications to other pathologies considering that IGF1
has been shown to be effective in other disorders of the autism spectrum.
Keywords: Rett syndrome, insulin-like growth factor 1, social cognition, seizures, autonomic functions
INTRODUCTION
The clinical case study performed in this experiment depicts the
efficacy and safety of insulin-like growth factor 1 (IGF1) exposure
upon two cycles of treatment. The patient is a young girl with a
clinical and genetic diagnosis of Rett syndrome (RTT). The study
started when the patient was 5 years old. The patient received first
round of treatment on the 25th of May 2010 and discontinued
on the 11th of November 2010. The second round of treatment
started on the 20th of November 2012 and discontinued on the
28th of February 2013.
BACKGROUND
Rett syndrome is taxonomized as a pervasive neurodevelopmen-
tal disorder affecting mainly female children (1:10000) due to its
X-linked method of inheritance (1). Methy-CpG binding protein
2 (MeCP2) dysfunction is associated with several neurodevelop-
mental disorders (1), and can cause a wide variety of phenotypes in
females. Most males do not live past the first year due to neonatal
encephalopathy and death in the classic RTT karyotype (2). The
effects of MECP2 mutations lead to a loss of function or overex-
pression of the MeCP2 protein. If it results in a loss of function
state, some examples of effects yield: classic RTT, atypical RTT,
autism, and mild mental retardation (2). The majority of RTT
patients (85%) have mutations in the MECP2 gene that lead to
loss of MECP2 protein function. At this point of time, there is no
cure to RTT syndrome, however treatment strategies are starting
to emerge.
Rett syndrome is a progressive neurodevelopmental disorder
that initially presents in females just past 18 months. Patients with
RTT appear to have apparent normal development and milestone
achievements up to the first 18 months of age (3). Early indication
of neurological disease progression includes: deceleration of head
growth, general growth retardation, weight loss, and weak posture
via muscle hypotonia (2). Progression of RTT leads to the loss of
purposeful use of their hands and the development of stereotypic
hand wringing or washing movements: other hand movements are
clapping, flapping, and mouthing (2). Withdrawal of social behav-
iors are noticeable where patients have shown symptoms such as
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irritability, self-abusive mannerisms, blank faces, audio hypersen-
sitivity, reduction of eye contact, unresponsiveness to social cues,
and indifference to variable environments (2). Eventual losses in
motor coordination, ataxia, and gait apraxia are symptoms of
motor pathway deterioration (2). Most girls eventually require
wheel chair assistance during teenage years. Autonomic pertur-
bations include hyperventilation (and other breathing abnormal-
ities), seizures with variable severity, cardiac abnormalities, con-
stipation, parkinsonian features, and oropharyngeal dysfunction
(2). Patients may have a normal appetite but still experience weight
loss and osteopenia. Structural abnormalities include scoliosis and
rigidity. Behavioral complications involve teeth grinding, tem-
per tantrums, depression, and anxiety. The condition eventually
plateaus and the patient may live up to their seventh decade (2).
MeCP2 is an example of a mammalian protein that binds to
methylated CpGs. For its ability to bind DNA and influence gene
expression, MeCP2 is mostly believed to be a transcription factor
(1), however localization of MeCP2 outside the nucleus and in
the synaptic compartments (4) suggest that MeCP2 protein may
have also functions directly related to synaptic activity. Inheritance
of the MECP2 gene follows an X-linked dominant pattern and
sporadic mutations are prevalent in 85% of classic RTT cases (2).
Mutations that have been noted on the spectrum include missense,
nonsense, and frame shift mutations for this protein. Mutations
impacting on the nuclear localization sequence of MeCP2 or early
truncating mutations have more severe phenotypes in compari-
son to missense mutations; while C-terminal deletions are thought
to cause milder phenotypes. There is an association between the
severity of the mutation and the severity of the phenotype (5).
The phenotype of the female is highly variable depending on the
expression levels of the unaffected copy of MECP2 on the other X
chromosome.
The identification of the gene associated with Rett made possi-
ble the generation of mutant mice defective in MeCP2 functions.
The mice have signs that resemble patients’ symptoms and there-
fore constitute a valid model for the study of neurobiology of
Rett and for testing candidate therapeutics. A significant discovery
has emerged from two independent groups concluding that in the
mouse model, the reactivation of the natural Mecp2 gene in the
adult mutant mice partially reestablished normal phenotype (6, 7).
This finding implies that when the normal brain has impairment
by a dysfunctional MeCP2, control conditions can be restored in
the central nervous system. However, Zoghbi’s lab has shown that
drug treatment for RTT has to be administered during the whole
life of the patients (8).
Neurobiological analysis shows that MeCP2 mutations pro-
duce defects in central nervous system development, specifically in
the maturation of circuits and synapses (4, 9). Therefore, medical
treatments focused on brain development and synaptic function-
ing is promising for the regression of RTT. Indeed, a research study
noted that overexpression of brain-derived neurotrophic growth
factor (BDNF), which is a neurotrophin that has involvement in
brain development and plasticity, resulted in the neutralization of
the MeCP2 deficiency (10). This allowed for the consideration of
growth factors, which are centralized around their involvement of
neuronal and synaptic growth, toward potential treatment options
for RTT syndrome. BDNF is incapable of crossing the blood brain
barrier, so it is of no use for immediate pharmacological therapy
consideration. However, IGF1 and its active peptide (1–3) IGF1,
are capable of crossing the blood brain barrier. This quality makes
them an ideal drug for treatment in neurodevelopmental disorders
like RTT. Research has shown that IGF1 peptide treatment par-
tially restored spine density and synaptic amplitude in the mouse
model (9). The treatment was started at 2 weeks of age and was
noted to stabilize cortical plasticity to the wild-type level. One of
the major effects noted in this study was after the treatment of
IGF1; MeCP2 KO with treatment mice improved from an average
of 60-day lifespan to an average of 90-day lifespan in comparison
with KO without treatment mice. Not only did the KO mice with
treatment have increased life span, but also improved respiratory,
cardiac, and locomotor function. In the study from Tropea et al.
(9) (1–3) IGF1, has already shown to ameliorate the symptoms of
RTT in the mouse model of the disease. IGF1 has also been shown
to be an effective therapy in MeCP2 KO mice (11). Other studies
show that IGF1 is a suitable treatment for human RTT patients
and that there are no known risks associated with IGF1 adminis-
tration (12, 13). In our previous study, six girls with classic RTT,
between 4 and 11 years of age, were administered IGF1 subcuta-
neously twice per day for 6 months. They were evaluated based on
the effectiveness of the treatment and it was reported that IGF1
partially restored a significant amount of the symptoms of RTT.
From this study, all families and caretakers noticed an improve-
ment in cognitive abilities of the girls and their interactions with
the surrounding environment. Considered McGraw’s study, life-
long therapy is necessary to combat RTT syndrome, like IGF1 for
MeCP2 dysfunction (8).
The aim of this paper is to evaluate if repeated cycles of IGF1 is
a suitable method, in respect to safety and efficacy, for a life-long
treatment option in the human model. The clinical case study in
this report depicts a patient receiving two cycles of IGF1 treat-
ment and clinical parameter assessments. Also, we provide insight
on how the patient responds after the treatment with two clin-
ical evaluations after the treatment cycles. The study is an open
label study, and the child displays classic RTT syndrome, where
the phenotypic onset of the disease took place between the eighth
and ninth month. The child started the first IGF1 cycle in May
2010, when the child was in the fifth year of age. IGF1 was adminis-
tered twice daily (0.1 mg/kg) for 6 months. Two years later, another
cycle of treatment was started. The dosage and routes of admin-
istration were the same, but the second cycle lasted 4 months. In
between each cycle, blood parameters were monitored and auto-
nomic responses evaluated. During both cycles, IGF1 was well
tolerated in each cycle and no direct side effect was observed. IGF1
is also shown to cause no interference with the anti-epileptic med-
ications that the patient was undergoing. Based on the conclusion
of this experiment, the treatment is believed to promise a strong
impact on RTT syndrome.
SUBJECTS AND METHODS
CLINICAL ANALYSIS
We evaluated the RTT patient’s overall physical health, RTT-
associated phenotypic expressions of the patient, and growth
developments. We took notes, recorded in the Section “Results,”
during various stages of the treatment process during two cycles
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of IGF1 exposure. The parents kept a diary with daily annotations
of glycemia levels and alterations in behavior (sleep, eating, etc.)
Patient screening
Patient was chosen based on the presentation of classic RTT
syndrome and confirmed mutation in the MECP2 gene. The
family gave written consent for partaking in this study before
any treatment took place. The selection criteria are described in
Pini et al. (12).
Treatment administration
Mecasermin–Increlex (IGF1) was subcutaneously administered
twice daily (0.1 mg/kg) in two cycles: the first cycle lasted nearly
6 months, and the second cycle lasted 4 months, with a 2 years
gap between the two cycles. Possible side effects include hypo-
glycemia (headache, dizziness, nausea, and perspiration), tonsil
hypertrophia, and local irritation at the injection site. The family
was thoroughly informed about the treatment process; the care-
takers of the patient were trained to perform daily injections, and
were provided with a kit to measure glycemic levels. Patients were
observed for side effects during every visit and critical events were
recorded and are in summarized in the Section “Results.”
Post treatment examination
The patient was followed up twice after each cycle to evaluate
general health after IGF1 exposure. Patient was physically exam-
ined based on cardio-respiratory factors, body growth parameters,
and motor abilities. Critical events were recorded along with the
corresponding epileptic treatment at that time. Behavioral exam-
ination along the parameters of social interaction and mood were
also evaluated.
VIDEO ANALYSIS OF COGNITIVE AND SOCIAL ABILITIES
Video analysis utilized approximately 20 h of video recordings of
RTT patients and was filmed in Versilia Hospital (Italy). The RTT
patient observed in this paper was an analyzed participant in this
study. The investigators, analyzing the videos, were not aware that
the patient had received IGF1 treatment. Observed preliminary
footage from additional patients yielded the design of the scoring
criteria. It was decided to score the girls on 20 features,10 negatives,
and 10 positives. The patient was scored in each feature on a scale
from 1 to 5, with 1 indicating extreme RTT, 2 indicating severe RTT,
3 indicating moderate RTT,4 indicating mild RTT,and 5 indicating
absent RTT. In this way, a lower score was related to a more preva-
lent RTT-like behavior. The 10 negative features chosen were: hand
wringing, biting, rocking, hitting, indiscriminate moaning, tongue
chewing, vacant staring, bruxism, breath-holding/apnea, and Val-
salva maneuver. The 10 positive features chosen were: pointing,
manipulating, reaching for something, ability to mimic/imitate,
indicating yes/no with head gesture, reactivity to a call, reactivity to
an object, smiling in response to a stimulus,deliberate vocalization,
and attention.
RESULTS
The patient was born from the mother’s first pregnancy. The
mother suffers from epilepsy and was treated with anti-epileptic
drugs (AEDs) since adolescence. The patient was born at week 38
of gestation by cesarean section due to an emergency response. At
birth, the patient had the following dimensions: 2600 g in weight,
45.5 cm in length, and 33 cm in head circumference. The newborn
received artificial feeding due to maternal agalactia. At the approx-
imate age of 9 months, the child presented with: frequent pyloric
stenosis, decreased stimulus to environment, mentally absent, and
showed stereotypic hand to mouth and washing movements. The
patient’s motor development showed independent seat position-
ing acquired at 8 months with kyphosis of the bust: unimanual
walking with support at 18 months with mild postural tremor. At
18 months, the patient’s use of hands was discrete and she could
grab objects and press buttons. The patient’s language develop-
ment showed production of vocalization and infrequent simple
syllabic doublings (bi-bi-, ma-ma, ba-ba). The patient showed
bruxism with variable power. The patient had tendency to be con-
stipated and sphincter control was not acquired. The sleep–wake
rhythm was characterized by frequent nocturnal awakening and
was prescribed Niaprazine (Nopron). On the 2nd of August 2006,
genetic testing for RTT indicated a mutation c. 397C>T (R133C)
of exon 4 of the MECP2 gene.
The clinical case study performed in this experiment depicts
the efficacy and safety of IGF1 exposure upon two cycles of treat-
ment. Careful consideration was executed in monitoring to the
effects of IGF1 in both autonomic function and blood parame-
ters. The patient received first round of treatment on the 25th of
May 2010 and discontinued on the 11th of November 2010. The
second round of treatment started on the 20th of November 2012
and discontinued on the 28th of February 2013. The dosage for
IGF1 was the same in both cycles: 0.1 mg/kg maintenance dosages
and 0.05 mg/kg first and last weeks were adjustment dosages. Our
findings are noted below during each visit with the patient during
their cycles of IGF1 treatment.
FIRST CYCLE OF IGF1 TREATMENT
The first experimentation with IGF1 started on 25th of May 2010
(first cycle), when the patients were 5 years and 8 months. We
clinically assessed the patient and results were noted as follows:
patient has slight ataxic ambulation, which required minimum
support; slight hypotonia was noticeable and babinsky positive
ROT hyper-excitability; wide-spread bouts of tremor often asso-
ciated with tachypnea, and possible grasping of objects upon
request. Patient demonstrated expressive language, characterized
by varied and modulated vocalizations. The patient had a calm
demeanor with discreet interest in external environment and
surrounding people.
Second visit was on the 31st of August 2010. The patient
showed good clinical health and similar ambulation as the first
visit. The patient showed coastal navigation with the family. The
hypotonia and wide-spread tremor was the same as first visit. The
patient showed improvement in grip of objects. The patient con-
tinued to demonstrate expressive language, characterized by var-
ied and modulated vocalizations. Communicative intentions were
observed and actions were occasionally preceded by anticipatory
behaviors. The demeanor remained calm.
Third visit took place on the 23th of November 2010. The
patient maintained good general clinical condition and the par-
ents reported a good clinical outcome at home. The patient was
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able to ambulate with unimanual support with tendency to exter-
nally rotate the march of the lower limbs, and launch of the same.
The use of hands to engage in patterns of action with objects have
been a new observation, such as pressing a button or lever to get
a visual or sound effect. The patient demonstrates good conduct
and interaction with unfamiliar people. The food and sleep–wake
rhythm is regular, while obstinate constipation persists.
The patient was discontinued from IGF1 on the 27th of
November 2010 and clinical assessments were continued.
The fourth visit was on the 15th of February 2011. The clini-
cal observations were almost unchanged from the previous visit.
The gait seemed to have improved, even when the child fatigued
easily. There was a submission of critical events that took place.
On the 8th of February 2011, at 10:40 a.m. the first epileptic cri-
sis lasting 2–3 min was characterized by tremor, hypotonia, eyes
wide and staring into space. This was followed by sleep. Sec-
ondary crisis showed facial and perioral cyanosis, tremor, and
blank stares, followed by sleep. A third crisis at 6:10 p.m. noted
guttural verses, staring, stiffening, and blank stares followed by
sleep. A fourth crisis occurred at 7:30 p.m. where stiffening, star-
ing, perioral cyanosis, pallor of the face, and strange vocalizations
followed by sleep. Vomiting, facial and perioral cyanosis, and gut-
tural sounds characterized the fifth crisis at 9:30 p.m. On the 9th
of February 2011, the patient had a fever of 37.3°C. At 12:35 p.m.,
the first crisis lasted a minute and was characterized by salivation,
perioral and facial cyanosis, absent eyes, and potential hypotonia
causing the patient to fold on itself.
The second crisis (on February 9th) occurred at 1:38 p.m. and
lasted 3 min; characterized by perioral and facial cyanosis and
mouth tremors followed by sleep. The third crisis occurred at 5:27
p.m. and lasted for 2 min, characterized by an absent gaze. On
the 11th of February 2011 at 10:16 a.m., the patient was noticed
to have staring eyes and making guttural sob like sounds. On the
12th of February 2011 at 10:00 a.m., the patient woke up with a
frightened look, began trembling with tears, and guttural vocaliza-
tions. A second crisis occurred at 3:40 p.m. characterized by neck
muscle failure and appearance of sleep while sitting on the toi-
let, with guttural vocalizations. On the 13th of February 2011, the
patient presented with a fever of 38.3°C, pharyngitis, and began
Zithromax treatment.
The fifth visit took place on the 24th of May 2011. The clinical
examination showed good general condition and parents reported
a stable clinical experience. The child had unimanual-supported
ambulation with tendency to externally rotate and launch of the
lower limbs. The clinician noted a decreased resistance during
walking. The patient was observed to have a discreet use of hands
when she grabbed objects and pressed buttons to get a visual or
sound effect. Social interaction showed observation of the envi-
ronment and the maintenance of eye contact for a longer duration
of time. The patient maintained a serene mood. The food and
sleep–wake rhythm were regular and constipation still persisted.
Critical incidents occurred almost daily and were characterized
by staring, gaze deviation to the left, and clonus of the limbs.
On the 13th of April 2011, the child presented a crisis with the
semiotics for a 10-min period, which required Micronoan admin-
istration. The patient’s anti-epileptic therapy dosage was increased:
valproate 200+ 200 mg/day.
The sixth visit took place on the 21st of October 2011. The
clinical examination reported a good general clinical condition.
The parents informed that the child was attentive, observational
of the environment, interacting with people, and mood was serene.
The critical events were reported to occur on awakening and
were characterized by wide-eyed, clonus of the limbs, apnea, and
cyanosis of the face. The patient then took Valproate: dosage of
250+ 200 mg/day.
Upon collection of the clinical data set for the first cycle,
blood test showed no morbidity related to the treatment and a
noticeable improvement in bone density. Glycemic values taken
during each visit all remained well within reference value (60–
110 mg/dl), where the patients’ average was 80 mg/dl and the range
was between 75 and 86 mg/dl. The starting bone density measure-
ment was taken on the 26th of May 2010 and a second one was
taken at the end of first cycle on the 15th of February 2011. This
measurement showed a BMD of 0.333 and 0.451, respectively.
Analysis of cognitive and social abilities show mixed results in
positive and negative RTT features, in terms of improvement and
disease progression (Figures 1 and 2). Figures 1 and 2, represent-
ing video analysis, note that the negative features (9 out of 10)
increased more than positive features (5 out of 10). Hitting and
breath-holding/apnea were the most improved negative features.
Smiling in response to a stimulation, deliberate vocalization, and
yes/no with head gesture were the most improved positive features.
The patient shows an improvement in height percentile during the
course of IGF1 treatment in almost immediate results, however,
it returned to previous percentile among the discontinuation of
the IGF1 treatment. No other significant correlations to the IGF1
treatment can be made from Table 1. In the ISS evaluation, we
noted a starting score of 4 in autonomic function, at the first
dose of the cycle; and upon the last dose, the patient reduced to
a score of 3 in autonomic function. This implies that the auto-
nomic function restored as a result of IGF1 treatment. Another
improvement noted by the ISS score was in growth and devel-
opment from an ISS score of 6, at first treatment, to a score of
5, at last dosage. This also implies that IGF1 treatment improved
the patient’s growth and development. ISS scores are shown in
Figure 3.
SUMMARY OF IGF1 EFFECTS AFTER THE FIRST CYCLE OF TREATMENT
We found that IGF1 was well tolerated during the first cycle of
treatment and did not show any side affect. The treatment pro-
duced an increase in height and BMI of the patient mostly during
the first 3 months of treatment, and returned to baseline after the
discontinuation of the drug (Tables 1 and 4). Significant benefits
were noted as reduction of negative stereotypes, while the social
and cognitive abilities did not show any significant improvement
(Figures 1 and 2; Table 5). IGF1 did not show any significant effect
on ISS, with the exception of the autonomic function, that appear
improved also after 6 months from the last IGF1 administration
(Figure 3; Table 6).
SECOND CYCLE OF IGF1 TREATMENT
The next cycle of IGF1 treatment started on the 20th of Novem-
ber 2012, when the patient was 8 years and 2 months. Since the last
visit, the patient is continuing the anti-epileptic therapy: Valproate
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FIGURE 1 | IGF1 treatment affects different features in different cycles.
Comparison of the scores of individual features at T0 and T1 for negative
(A) and positive (B) features in cycle 1 (left) and cycle 2 (right). Paired
comparison with Wilcoxon test shows that IGF1 treatment improved
significantly negative features in cycle 1 (Wilcoxon test, p-value=0.014),
but not in cycle 2 (Wilcoxon test, p-value=0.07). Viceversa, for positive
features the effect was significant in cycle 2 (Wilcoxon test,
p-value=0.016), but not in cycle 1 (0.3).
FIGURE 2 | Effects of IGF1 treatment differ in different treatment
cycles. Plots of average (T1–T0) and SE in cycle 1 and cycle 2 for
Negative features (A), Positive features (B), and Negative plus positive
features (C). The data suggest that the negative features improved more
in the first cycle than in the second (A). Conversely, the positive features
improved more in the second cycle than the first. (B) Considering both
positive and negative features, the effect of the treatment was
comparable in both cycles (C).
(250+ 200 mg/day) and Levetiracetam (300+ 300 mg/day). The
clinical examination shows that health is fair and reported: patient
has slight ataxic ambulation, which required minimum support;
slight hypotonia was noticeable and Babinski positive ROT hyper-
excitability; wide-spread bouts of tremor often associated with
tachypnea; and possible grasping of objects upon request, but
released after a few seconds. The patient has expressive language
that is characterized by production of varied and modulated vocal-
izations. The mood of the patient is serene and there is a discreet
interest in the environment and in surrounding people.
The second visit of the second cycle took place on the
29th of January 2013. The patient continues to have seizures
three to four times a week characterized by eyes turned
in backwards. The patient has an increased in dosage of
Levetiracetam (350+ 350 mg/day) and maintained Valproate
(250+ 200 mg/day). The parents reported an increase in bruxism
with a decrease in stereotypic mannerisms. The patient showed
longer attention span, improved eye contact, and smiling. The
dietary intake was good and constipation improved. The clinical
examination reported: patient has slight ataxic ambulation, which
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required minimum support; slight hypotonia was noticeable and
Babinski positive ROT hyper-excitability; wide-spread bouts of
tremor often associated with tachypnea; and possible grasping of
objects upon request, but released after a few seconds. The patient
had expressive language characterized by production of varied
and modulated vocalizations. The mood of the patient was serene
and there was a discreet interest in the environment and in sur-
rounding people. We took extra note in the slight improvement
of attention: specifically indicating that the patient holds her gaze
for the duration of the smile and she seems more interested in the
environment. Motor stereotypes decreased slightly while bruxism
increased.
The third visit took place on the 3rd of December 2013. The
grandfather informs about an improvement in attention span to
external stimuli throughout the visual field laterally. The commu-
nication capability is improved and characterized by the improved
ability to stare at an object that the patient wants to play with or
a place that the patient wants to go. He also noticed an improved
grip on objects. The mother reports that the patient eats less and
tremors and bruxism have increased. She also states that sleep
patterns are altered by presence of numerous episodes of pavor
during sleep and wake states. The clinical examination reported:
Table 1 | Growth parameters during first cycle of treatment.
Visit Weight
(kg)
Percen-
tile
Height
(cm)
Percen-
tile
Head
circum-
ference
Percen-
tile
BMI
1 14.2 4 104.5 4 48 2 13
2 15.2 4 108 10 48 2 13.03
3 17 4 108.5 10 48 2 14.5
4 17 4 108.5 10 48.4 2 14.5
5 16.7 4 110.6 4 48.4 2 13.8
This table compares the growth parameters of the RTT patient in the first cycle
with the average child of same age.The patient remains in low percentiles, despite
improvements in height during IGF1 application.
patient has slight ataxic ambulation, which required minimum
support; slight hypotonia was noticeable and Babinski positive
ROT hyper-excitability; wide-spread bouts of tremor often asso-
ciated with tachypnea; and possible grasping of objects upon
request, but released after a few seconds. The patient has expressive
language that is characterized by production of varied and modu-
lated vocalizations. The mood of the patient is serene and there is
a discreet interest in the environment and in surrounding people.
The clinician took another extra note in the slight improvement of
attention: specifically indicating, again, that the patient holds her
gaze for the duration of the smile and she seems more interested
in the environment. Motor stereotypes decreased slightly while
bruxism increased.
Suspension of the second cycle of IGF1 occurred on the 28th
of February 2013.
The following clinical observation was recorded on the 21st of
May 2013. An anamnestic incident was recorded with a slightly
increased frequency of seizures and every crisis has a longer dura-
tion of action. There is a constant intense tremor present. Parents
observe the patient suffering from pharyngitis and a decrease in
appetite. The clinical observation includes the patient being pale
and sleepy, while being poorly responsive to environmental stim-
ulation. They informed about two critical episodes in the morning
with semiology and in few seconds durations. The gait was possible
with minimal support and appeared ataxic. Slight hypotonia was
noticeable and Babinski positive ROT hyper-excitability. Wide-
spread bouts of tremor were noted in association with tachypnea.
There was grasping of objects on presentation, but released after a
few seconds. The stereotypes were unchanged.
Clinical data sets provided no insight into the second cycle of
IGF1 treatment in blood work or growth parameters (Table 2).
Glycemic values taken during each visit all remained well within
reference value (60–110 mg/dl), where the patients’ average was
78.2 mg/dl and the range was between 73 and 84 mg/dl. The start-
ing bone density measurement was taken on the 20th of November
2012 and a second one was taken at the end of the second cycle on
the 21st of May 2013. This measurement showed a BMD of 0.426
and 0.465, respectively.
FIGURE 3 | ISS scores plots during IGF1 cycles of treatment. ISS scores
reveal that IGF1 improves autonomic function. Plots of International Severity
Scale (ISS) score at each visit during cycle 1 (left) and cycle 2 (right) of IGF1
administration. Gray rectangles show the IGF1 Administration. Higher scores
represent worst performance. In both cycles, the IGF1 treatment improved
the autonomic function, while the other parameters remain unchanged or
worsened between the beginning and the ending of each cycle. Note that the
improvement is not maintained between cycles.
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Table 2 | Growth parameters during second cycle of treatment.
Visit Weight
(kg)
Percen-
tile
Height
(cm)
Percen-
tile
Head
circum-
ference
Percen-
tile
BMI
1 and 2 15 3 115 4 48 2 11.3
3 16 3 118.5 5 48.2 2 11.5
4 16.1 3 118.5 4 48.2 2 11.5
5 15.4 2 119.4 3 48.2 2 10.8
This table shows the growth parameters during the second cycle of IGF1 treat-
ment. There are no significant contributions to these characteristics given by
the treatment. The patient maintains in low percentiles during the second IGF1
treatment cycle.
The patient shows mixed results for positive and negative phe-
notypes based on the video analysis (Figures 1 and 2), however
no adverse effects are noted in association with the second cycle
of IGF1 treatment. Figures 1 and 2, representing video analysis,
note that the negative features (4 out of 10) increased less than
positive features (6 out of 10). Hand wringing and biting showed
most improvement in negative features. Reactivity to an object and
deliberate vocalization showed the most improvement in positive
features. In the ISS evaluation: we noted a starting score of 6 in
autonomic function, at the first dose of the cycle; and upon the
last dose, the patient reduced to a score of 5 in autonomic func-
tion. This implies that the autonomic function restored, again, as a
result of IGF1 treatment. Another consistent improvement noted
by the ISS score was in growth and development from an ISS score
of 6, at first treatment, to a score of 5, at last dosage. This also
implies that IGF1 treatment improved the patient’s growth and
development. ISS scores are shown in Figure 3.
SUMMARY OF IGF1 EFFECTS AFTER THE SECOND CYCLE OF TREATMENT
In the second cycle of treatment, there were no significant effects
of IGF1 on the growth parameters of the patient (Tables 1 and 4).
The scoring of the cognitive and social abilities, as well as the neg-
ative features of Rett, shows a general worsening of the conditions
between the end of the first cycle and the starting of the second
cycle of treatment. The second treatment with IGF1 produces a
significant improvement in the scoring for the social and cogni-
tive abilities, but no effects are visible on the negative symptoms
of RTT (Figures 1 and 2; Table 6). The ISS components show a
mixed effect of IGF1 on different features, with overall a long term
improvement of movement and autonomic functions (Figure 3;
Table 5).
FOLLOW-UP EXAMINATIONS POST CYCLES
On September 24, 2013, the patient was 9 years old with a body
mass index of 10.13 (normal values between 19 and 25 kg/m2).
The occipital–frontal cortex circumference was 48.2 cm and her
weight was 14.6 kg. The patient’s results in this report came from
the evaluations of the autonomic nervous system in quiet condi-
tions. Table 3 depicts the cardiovascular examination that took
place on this date.
The results showed normal breathing patterns for 21.2–35.9%
of mixed tachypnea breath, 12.2% of deep breaths, 7.4% of
Table 3 | Cardiovascular reflexes range during cycles.
Cardiovascular reflexes Examined values Normal values
Cardiac vagal tone 5.63 6–19
Heart rate 90.1 beats/min 60–140 beats/min
Respiratory rate 20 breaths/min 18–28 breaths/min
This table depicts that the patient falls with in the normal reference range for
three out of the four cardiovascular reflexes that we observed. Cardiac vagal tone
is just slightly under the reference value.
breath-holding episodes, 8% of hyperpnea, and 3.8% of apnea
episodes. The average heart rate recorded is about 90 beats per
minute, while the mean values of CVT in relaxation amounted in
about 5.6; where the registered CVT peaks results are of average
and significant.
The phenotype of the cardiopulmonary patient was classified
as forced (40.2%). The general autonomic framework was that
of a basal level vagal tone, which is slightly lower than normal.
There were multiple types of respiratory rhythm abnormalities
that were indicative of instability within the respiratory centers of
the brainstem.
On 11 March 2014, a second follow-up examination was
recorded. The parents noted some changes in seizure related
events. Since November of 2013, the patient took Carbamazepine
(25 mg in the morning and 50 mg in the evening), which was sus-
pended while being treated with Levetiracetam. The latest crisis
occurred a week before this examination where the patient had
a cluster of six episodes on the same day. The patient grew agi-
tated and had difficulty falling asleep, so Valium was given by the
parents.
At this time, the patient was currently attending third grade
class with support and rehabilitative physiotherapy continues
2 days a week (partially at ASL and partially privately) with swim-
ming integrated. She was on the following AEDs: depakote (250 mg
in morning and 250 mg in the evening), Carbamazepine (5 mg in
morning and 50 mg in the evening), and Pepidax.
The general health conditions were satisfactory. The patient was
able to autonomously maintain the sitting position with ataxia of
the trunk and ambulation requires support. Tremors were noticed
and the detection of bruxism. Scoliosis was absent, while there was
reduced muscle tropism. The patient made little facial expression,
with eye contact being only possible if the child is evoked several
times; language was absent. During the visit, there were no man-
ual stereotypes; however, the parents report it occurred when the
patient was tired. The patient showed fluctuation in vigilance, and
during the visit the child was alert and responsive. During neuro-
logical examinations, the child had suddenly fallen asleep for few
minutes at a couple of occasions. The physician recommended
that it was advisable for the patient to continue the rehabilitation
treatment that was already in progress.
COMPARISON OF IGF1 EFFECTS DURING AND AFTER THE TWO CYCLES
In order to compare the effects of IGF1 between the two cycles,
we considered the relative values of each parameter (growth para-
meters, ISS scores, cognitive, and social abilities scores) during
and after the termination of the drug administration, grouping
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together the effects during IGF1 administration and after the sus-
pension of the drug (Figure 4). In particular, for the effects during
the two cycles, was considered the differences between the last visit
during treatment and the visit before treatment (Figure 4A). For
the preservation of the effects after the cycles, we considered the
difference between the values at the last visit post treatment and the
values of the last visit during treatment (Figure 4B). We observed
that the effects of the drug were comparable between the two cycles,
and even with a slight positive effect during the first cycle, there
were no significant differences (two tailed t -test, p-value= 0.28).
EPILEPTIC HISTORY DURING OBSERVATION
The patient was enlisted into the study in March 2010, but because
of an onset of epilepsy during this month the start treatment was
postponed to May. There were two critical incidents between the
months of March to May and on average the crisis occurred at a
frequency of four/month. The patient then commenced the first
cycle of IGF1 treatment on the 25th of May 2010. The epileptic
treatment during this time was Valproate. From the time of the
previous visit to the next visit on the 31st of August 2010, there
were five critical episodes reported while on the Valproate ther-
apy, on average the crisis during IGF1 administration have the
same intensity and frequency than before the treatment. More
frequent critical incidents occurred between the second and third
visit, where the patient was on Valproate. Following this visit, there
was the suspension of IGF1 on the 27th of November in 2010. On
the fourth visit,15th of February 2011,after the suspension of IGF1
administration, the crisis appeared in clusters on several occasions.
At this point, the epileptic therapy was adjusted to Valproate plus
Frisium (for when the patient has many crises). By the fifth visit
on the 24th of May 2011, critical episodes became more frequents
and occurred on almost a daily basis. The therapy was Valproate,
while Frisium was suspended. Visit six, on the 21st of October
2011, indicated critical episodes occurring upon awakening. Still
the patient remained on Valproate.
The second trial start date occurred on the 20th of November
of 2012. Critical episodes are daily and the epileptic therapy was
Valproate and Levatiracetam. The second visit showed similar crit-
ical episodes on a daily basis. Suspension of IGF1 occurred on the
FIGURE 4 |The effects of IGF1 treatment for each cycle are
comparable. The plots represent the differential scores of growth
parameters, ISS scores and Social and cognitive scores, before and after
IGF1 Administration [EFFECTS (A)], and in follow-up studies [PRESERVE
(B)]. Although we observe a slightly major efficacy of IGF1 during the first
cycle of treatment, the differences are limited and they are not significant.
28th of February 2013. The third visit took place on the 12th of
March 2013, where the critical episodes remain daily. The crisis
did not change with the administration of IGF1 treatment and the
epileptic therapy remained on Valproate and Levatiracetam. On
the 24th of September 2013, the critical episodes were reported
the same on a daily basis. During this fourth visit, the patient was
on the same epileptic treatment. On the 28th of October 2013, the
epileptic therapy was changed: Levitiracetam was removed and
Carbamazepine was added. The sixth visit, on the 3rd of Novem-
ber 2014, reported that Carbamazepine caused a thinning out of
critical episodes, but they were clustered. The epileptic therapy was
carbamazepine and valproic acid.
DISCUSSION
The use of IGF1 represents an appealing therapy for RTT. Due
to IGF1 affecting multiple symptoms of RTT in animal models,
its noticeable benefits from pediatric use, and its physical prop-
erties allowing it to cross the blood brain barrier; pilot trials (12,
13), indicated that IGF1 is safe and tolerable for treatment of RTT
patients.
Considering the finding that any treatment for RTT should
be administered for life (8), our research addresses the issue of
multiple IGF1 treatments and tolerability in children with RTT
syndrome. During our first study (12), we observed the major
improvements during the first weeks of IGF1 treatment, and for
this reason, we decided to reduce the time of the second treatment
to 20 weeks. These findings are in line with the study by Khwaja
et al. (13), where the amount of IGF1 in the serum decreases dur-
ing the administration period, and the authors suggest that an
adjustment of the dosage and administration time could be more
beneficial to the Rett patients.
Although our study is mostly oriented in confirming the safety
and tolerability of IGF1 through multiple cycles, we observed an
overall improvement of autonomic function during IGF1 treat-
ment, and then a lessening of improvement upon suspension of
IGF1 (Figure 3; Table 5). We recorded no hypoglycemia, which
indicates that IGF1 shows good toleration in patients. This is
important because it is one of the main risks associated with IGF1
treatment (13).
Table 4 | Differential scores of growth parameters during cycles.
Growth parameters Cycle 1 Cycle 2
Differential score Effect Preserve Effect Preserve
Weight 2.8 −0.3 1 −0.6
Height 4 2.1 3.5 0.9
Head circumference 0 0.4 0.2 0
BMI 1.5 −0.7 0.2 −0.7
This table summarizes the differential scores for each component of the growth
(listed on the left), considering the difference at the end versus the beginning of
the treatment (effect) and the difference after 6 months from the last administra-
tion versus the scores on the day of the last administration (preserve).The original
scores are those reported inTables 1 and 2.The improvements are highlighted in
green, and the worsenings are highlighted in red.
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In this study, similarly to what reported in the past and by
other researchers (12, 13), we did not observed any specific influ-
ence of IGF1 treatment on epileptic episodes: the appearance of
the epileptic crisis preceded the first cycle of IGF1 administration,
and the intensity and frequency of the episodes remained on aver-
age the same before and after the treatment. The intense episodes
reported between the second and third week during the first cycle
of treatment, can be due to an endogeneous evolution of the crisis,
as suggested also by the increased frequency after the interruption
of the treatment (which required an adjustment of the therapy).
Before starting the second IGF1 administration, the crisis had a
daily frequency and they remained unaltered during the whole
cycle of treatment. These observations are in accordance to the lit-
erature in pediatric syndromes, where IGF1 is not associated to an
increase in seizures, but rather epileptic phenotype is associated to
decreased IGF1 levels in the serum (14, 15). On the contrary, it is
possible that the seizure medication hindered the positive effects
of IGF1. It would be interesting to compare the effects of IGF1
administration in patients treated with valproate versus patients
treated with alternative AEDs.
Insulin-like growth factor 1 has also been considered to be more
effective when given in acute intermittent pulses, versus chronic
dosing. One noted side effect from IGF1, was that long term IGF1
administration has linkage with potential puberty effects; which
is already accelerated in RTT (13). Being that IGF1 has a strong
feedback system, patient tolerance over cycles is worth exploring
into for future studies. This implies the evaluation of lower doses
in life-long treatment. An assessment of total effects on single ana-
lyzed relative parameters (ISS scores, cognitive and social abilities,
and growth parameters) showed that the effects observed with
the first cycle of treatment were not significantly different from
those in the second cycle of treatment (Figure 4, two tailed t -test
p-value= 0.28).
While there were some phenotypic benefits shown by the assess-
ment of social and cognitive abilities, nine of the improvements
remained after the first cycle was over, and no phenotypic
improvement remained in the second trial as different phenotypes
improved aside from attention. However, we observed motor con-
trol as another form of improvement. However, our research
insight into motor control improvement may be a result of subjec-
tivity further research is suggested to elucidate the validity of this
potential benefit. Our analysis confirms the results of Zoghbi’s
team, that whatever treatment is decided for RTT syndrome
patients, it must be for life (8).
The two studies of IGF1 safety and tolerability in RTT patients
(12, 13), showed similar results: IGF1 did not produce hypo-
glycemia and it is not associated to seizures, and overall is well
tolerated by patients. In addition, we observed an improvement in
autonomic function, and Khwaja and colleagues concluded that
motor ability showed no measurable improvement, but also found
Table 6 | Differential scores of ISS scores during cycles.
ISS components Cycle 1 Cycle 2
Differential score Effect Preserve Effect Preserve
Growth and development −1 1 −1 2
Locomotor apparatus 0 0 0 0
Movement 0 0 0 −1
Cortical function 1 0 −1 1
Autonomic function −1 0 0 −1
This table summarizes the differential scores for each component of the ISS (listed
on the left), considering the difference at the end versus the beginning of the
treatment (effect) and the difference after 6 months from the last administration
versus the scores on the day of the last administration (preserve). The improve-
ments are highlighted in green, and the worsenings are highlighted in red. Note
that the decrease in the scoring are improvements for the ISS; on the contrary,
increases in the scoring represent worsening.
Table 5 | Differential scores of social and cognitive abilities during cycles.
(T1–T0) score Negative features (T1–T0) score Positive features
Cycle 1 Cycle 2 Cycle 1 Cycle 2
Hand wringing 0.67 2.33 Pointing 0.00 0.00
Biting 1.33 1.67 Manipulating −0.17 0.83
Rocking 0.50 −0.33 Reaching for something 0.50 0.50
Hitting 1.83 1.33 Ability to mimic/imitate −0.33 0.67
Indiscriminate moaning 0.67 −0.67 Yes/No with head gesture 1.00 0.00
Tongue chewing 0.33 0.17 Reactivity to a call −0.17 0.00
Vacant staring −1.17 1.67 Reactivity to an object 0.00 1.33
Bruxism 1.50 −0.67 Smiling in response to a Stim 0.83 0.00
Breath-holding/apnea 1.50 −1.33 Deliberate vocalization 0.67 1.17
Valsalva maneuver 0.33 −0.50 Attention 0.33 0.67
Overall 7.83 3.67 Overall 3.17 5.17
This table summarizes the differential scores for negative and positive features of the social and cognitive abilities assessment. Each number represents the difference
of the score for the specific ability at the end of the treatment (T1) versus the beginning of the treatment (T0). Improvements are therefore positive numbers and
they are highlighted in green, while worsening are negative numbers and are highlighted in red.
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that respiratory complications associated with RTT syndrome
showed improvement (13).
One factor to consider in our findings is the environmen-
tal surrounding that the patient experienced during and after
the IGF1 treatment. The patient lived with the mother during
the time of treatment. The mother suffers from anxiety and
seizures, which may have limited the benefits of IGF1 treat-
ment due to high stress levels being perceived by the patient.
The consideration is due to a follow-up communication, post
IGF1 second cycle treatment, where the grandparents noted an
immediate amelioration of the patient’s phenotypic manner-
isms. The stressful environment could have caused misperception
of the severity level to phenotypic hindrances, which are RTT
associated.
The personal environmental surrounding, together with the
onset and progression of the epileptic crisis are two of the limits of
this case study for assessing the benefits of IGF1 therapy. Appro-
priate double blind and placebo controlled studies are necessary
to define the efficacy of IGF1 treatment. However, considering
the rarity of RTT (1:10,000), and the recent discovery of IGF1 as
possible Rett treatment, data coming from a single case study are
nonetheless useful to further develop the treatment.
Our research show that repeated treatments with IGF1 is safe
and tolerable for the patient. This finding along with other find-
ings on IGF1 treatment with RTT, should encourage further
research in IGF1 treatment for additional neurodevelopmental
disorders.
CONCLUDING REMARKS
Our research shows that repeated treatments with IGF1 are safe
and tolerable for the patient. We observed improved autonomic
function and social and cognitive abilities in each cycle but the ben-
efits were lost between cycles. The results in this clinical case study
suggest that IGF1 is beneficial for our patient, but a larger cohort
of patients and proper clinical trials are requested to establish the
overall efficacy in RTT.
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